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Abstract:  
Objectives: Although Alzheimer’s disease (AD) is the most common form of dementia in the 
elderly, its aetiology remains mostly unknown. A potential pathophysiological mechanism for 
AD arises from the knowledge that insulin is also synthesized independently in the central 
nervous system and is involved in the regulation of memory formation. AD may represent a 
brain-specific form of insulin resistance.  
Methods: We used immunohistochemistry to investigate the numbers of cells expressing 
insulin receptor -subunit (IR) and phosphorylated PPARγ (PPARγ(p)) in human post-
mortem tissue from patients with AD; AD combined with type 2 diabetes mellitus (T2DM); 
just T2DM, and from aged-matched controls. These numbers were evaluated in frontal cortex 
and in dorsal/ ventral parts of the hippocampus.  
Results: We observed significantly lower numbers of IR positive cells in AD cases 
compared to all other groups in all investigated brain regions. Also significantly more 
PPARγ(p) positive cells occurred in each patient group compared to control. 
Conclusions: T2DM and AD may not be directly linked, but may share common histological 
features including lower numbers of IRβ positive cells and higher numbers of PPARγ(p) 
positive cells in all investigated brain regions. These observations may at least partially 
explain the increased frequency of AD in elderly diabetic patients. 
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Introduction 
The association between type 2 diabetes mellitus (T2DM) and increased risk of dementia in 
the elderly is well documented (Biessels and Kappelle 2005; de la Monte and Wands 2005). 
Multiple possible mechanisms for this association have been proposed, including the direct 
effects of hyperglycaemia, insulin resistance, and insulin-induced amyloid-peptide 
amyloidosis in the brain (Luchsinger and Gustafson 2009). Alzheimer’s disease (AD) is the 
most common form of dementia in the elderly; despite decades of intense research, the 
aetiology of AD remains mostly unknown. Since insulin is also synthesised in the central 
nervous system and is involved in the regulation of several cell processes including memory 
formation, it may contribute to an underlying pathophysiological mechanism for AD.  
An early correlation between insulin receptor β-subunit (IRß) and AD arose in the mid-1980s 
when it was reported that the hippocampus and parts of the cerebral cortex, regions important 
to learning and memory, contained high densities of IRβ (Baskin et al 1987; Gammeltoft et al 
1985) . Insulin has dramatic effects on human cognition (Strachan et al 1997), and the actions 
of insulin and insulin-sensitising peroxisome proliferator-activated receptor-γ (PPARγ) 
agonists have been explored in AD patients (Watson and Craft 2003). The risk of AD and 
memory impairments is increased by hyperinsulinaemia and insulin resistance, characteristics 
of T2DM (Carlsson 2010; de la Monte 2009), which is associated with an increased risk of 
AD (Sims-Robinson et al 2010). These observations and other findings have led to the 
hypothesis that the cognitive deficits observed in AD may arise, in part, from insulin 
insensitivity in the brain.  
Glucose uptake and metabolism have been shown to be impaired in brain regions involved in 
memory and cognition in AD patients (Arnaiz et al 2001; Watson and Craft 2004). For 
example, insulin can act both in vitro and in AD patients to regulate amyloid β (Aβ) levels, 
and insulin may facilitate Aβ release and interfere with insulin degrading enzyme (IDE)-
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mediated degradation of Aβ (Qiu and Folstein 2006). In addition, vascular dysfunction 
associated with insulin resistance may also increase susceptibility to AD (J et al 2009; 
Umegaki 2009). The principal action of PPARγ agonists in the periphery of the body is to 
enhance insulin sensitivity and lower serum glucose levels, actions that underlie the efficacy 
of these drugs (Berger and Wagner 2002) and provide a rationale for the use of PPARγ 
agonists in treating AD.  
In this study, we focused on IRβ and phosphorylated PPARγ producing cells in human post-
mortem brain tissue. Using immunohistochemical staining against IRß and PPARγ(p) in brain 
tissue originating from patients with AD, with AD combined with T2DM, with T2DM, and 
from aged-matched controls, we evaluated the alterations of these proteins in the frontal 
cortex and in the dorsal and ventral parts of the hippocampus. 
Materials and Methods 
Sample preparation 
The brain samples used in this study were supplied by Brain Net Europe. The entire procedure 
was performed in accordance with the Helsinki Declaration in its latest version and with the 
Convention of the Council of Europe on Human Rights and Biomedicine. Clinical diagnosis 
of AD was based on NINCDS-ADRDA criteria and confirmed by neuropathological findings 
(Braak and Braak 1991).  
Histological samples were obtained from the dorsal and ventral hippocampus and from the 
prefrontal cortex of post-mortem brains from four patient groups (Supplementary Table S1): 
age-matched control patients without dementia, patients with T2DM, AD patients, and 
patients with AD plus T2DM. In preparation for routine neuropathological examination, the 
brain was divided midsagittally, and one hemisphere was immersed in 4.5% p-formaldehyde 
(Fischer GmbH, Saarbruecken, Germany) for 3-4 weeks.  
Immunohistochemistry  
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Paraffin sections (8 µm) of post-mortem brain tissue from the four patient groups were 
deparaffined with an alcohol dilution series. The slides were then boiled in 10 mM 
Citratbuffer  cointaing 10,51g citratmonohydrate and 2g sodium hydroxide pellets in 5l 
double distillate water (pH 6) for at least 10 min for antigen retrieval. The sections were 
washed three times in Tris-buffered saline, and non-specific binding was blocked with 
blocking solution (BS) containing 10% normal goat serum, 2% bovine serum albumin, and 
0.01% Triton-X 100 in Tris-buffered saline for 1 h before incubation with the various primary 
antibodies diluted in BS. The primary antibodies targeted the following proteins: IRß (Santa 
Cruz, Heidelberg, Germany), diluted 1:200; neuronal specific enolase (NSE; Abcam, 
Cambridge, UK), diluted 1:300; and PPARγ(p) (Abcam, Cambridge, UK), diluted 1:200 and 
all antibodies were incubated overnight at 4 °C. The primary antibodies were visualised with 
antibodies conjugated to Alexa® Fluor-488 (green) and Fluor-555 (red; Invitrogen, Darmstadt, 
Germany). All secondary antibodies were incubated for 2 h at room temperature in the dark. 
Finally, the sections were mounted on glass slides and cover slipped under Vectashield 
(Vector Labs, Eiching, Germany) for fluorescence microscopy.  
Automated cell counting 
Five images of each brain region from each patient were recorded and analysed with Cell^P 
(version 2.0; Olympus, Hamburg, Germany). We used Imaging C within Cell^P to use a 
macro recorder, to define special regions of interest for each investigated protein, and to 
perform automated cell counting. The total cell number for each image was determined, and 
we separately obtained counts for the special regions of interest for each image. Automated 
cell counting helped us maintain the standard error of measurement at the same level for 
image analyses. 
Statistical analysis 
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Immunohistochemistry images were analysed for the numbers of cells positive for NSE, IRβ, 
and PPARγ(p) staining in comparison to the total number of cells via analysis of variance 
(ANOVA) and a post-hoc Scheffé test with a significance level of p<0.05. Reported values 
were calculated in relative to control levels (100%). The statistical program Stat View 5.0 
(SAS Institute Inc. Cary, NC, USA) was used for all analyses. 
Results 
Figure 1 represents one example of histochemical staining for NSE in the prefrontal cortex of 
a control case. Fluorescent pictures were always recorded in gray values for counting. Each 
protein had its own specific counting parameters, which were computationally defined for 
automated counting.  
In order to ascertain that neuronal cell loss was not the predominant factor in our analysis of 
patient groups and control subjects, we stained all brain section slides (prefrontal cortex, 
dorsal and ventral hippocampus) with NSE antibody in all patient groups. In the prefrontal 
cortex we observed a minor but non-significant difference in the number of enumerated 
neurons in all three patients groups compared to the age-matched controls (Fig. 2). AD 
patients had 17% fewer NSE positive cells, AD plus T2DM patients had 10% fewer NSE-
positive cells, and T2DM patients had 15% fewer NSE-positive cells than the age-matched 
control subjects (Fig. 2). Compared to the control group, the dorsal and ventral hippocampus 
sections contained higher numbers of NSE positive cells in T2DM patients (24-28% more) 
and in patients with AD plus T2DM (14% more), but these differences were not statistically 
significant (Fig. 2). We used these brain regions for subsequent investigations because they 
were relatively unaffected by neuronal cell lost in all groups, enabling identification and 
confirmation of specific protein alterations. 
Cognitive function is an important parameter in the evaluation and determination of AD 
progression; the prefrontal cortex and hippocampus are critical regions in AD pathology, and 
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for this reason we focused our IRβ quantification on these brain areas. Patients with AD had 
50-60% fewer IRβ positive cells in the prefrontal cortex (p< 0.0001) compared to the control 
group as well as compared to the patients group with only T2DM and to the AD+T2DM 
combined group (Fig. 3). A 50% less IRβ in the dorsal (p= 0.003) and 60% less IRβ in the 
ventral hippocampus was found in comparison to the healthy control group (p< 0.0001) (Fig. 
3). While in the dorsal hippocampus we could find only a tendency for less IRβ positive cells 
in the AD group compared to the combined group (T=0.063). On the other hand, in ventral 
hippocampus a nominal significance reduction by 20% of IRβ positive cells was detected in 
the AD group in comparison to the combined group (p=0.0051) (Fig. 3).  Patients with T2DM 
alone possessed 32-35% fewer IRβ positive cells in the dorsal hippocampus (p= 0.031) and 
ventral (p= 0.0103) compared to control subjects (Fig. 3); these values in the same brain 
regions were 26% (p= 0.0157) and 27% (p= 0.0154) for patients with AD plus T2DM (Fig. 3).  
Gender-based differences in the number of IRβ positive cells were observed in AD patients 
(Supplementary Table S2). In all investigated brain regions, female AD patients had 
significantly fewer IRß-positive cells than male AD patients. In the prefrontal cortex females 
AD patients harboured 15% fewer IRß positive cells, in the dorsal hippocampus they had 16% 
fewer positive cells, and in the ventral hippocampus we observed 11% fewer positive cells. 
There was no significant relationship between age and IRβ level in any of the investigated 
brain regions (Supplementary Table S3).  
The most significant results involved the analysis of PPARγ(p) positive cells. We detected 
more than 60% more PPARγ(p) positive cells in all patients group (p< 0.001) compared with 
the control group (Fig. 4). There were no gender-specific differences in the number of 
PPARγ(p) positive cells in the cortex, but analysis of the dorsal and ventral hippocampus 
revealed significant differences (Supplementary Table S2). Female patients with T2DM had 
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10% fewer PPARγ(p) positive cells than male patients; in contrast, female AD patients 
possessed 13-18% more PPARγ(p) positive cells in these brain regions. 
Discussion 
Accumulating evidence supports the hypothesis that AD and T2DM share a common link (de 
la Monte 2009; J et al 2009; Sims-Robinson et al 2010); while aging is clearly the strongest 
risk factor for AD, emerging data suggest that T2DM and dyslipidaemic states can contribute 
substantially to AD pathogenesis either directly or as cofactors (Qiu et al 2007). Those 
observations are not without controversy, and a longitudinal survey revealed that although 
marginal diabetics had a significantly increased risk for future development of full diabetes, 
dementia, or AD, the risk effects were independent rather than linked (Xu et al 2007).  
In the present work we observed several common histological features in patients with 
diabetes and AD. In groups of patients with AD, with T2DM plus AD, and with T2DM alone, 
the number of IRβ positive cells in the hippocampus was significantly decreased compared to 
the control group (fig. 3). After evaluation of the total neuronal cell numbers in samples from 
all four groups, we were able to confirm that the number of IRβ positive cells was affected by 
AD and T2DM.  
Why should AD or T2DM patients have fewer IRβ positive brain cells compared to age-
adapted controls? AD is characterized both by low insulin levels and by insulin resistance 
within the central nervous system that causes a reduction in brain insulin. Several mechanisms 
may explain why insulin mediates memory facilitation. As noted, insulin receptors are found 
in brain areas responsible for cognition. Insulin activates signalling pathways associated with 
learning and long-term memory and helps to regulate processes such as neuronal survival, 
energy metabolism, and plasticity, processes that are required for learning and memory (Fig. 
5) (de la Monte and Tong 2009). Examination of post-mortem cases of late-stage AD 
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demonstrated that advanced AD was associated with strikingly reduced levels of insulin, IGF-
1 polypeptide, and related receptor genes in the whole brain (Steen et al 2005).  
In the current study we examined whether patients with T2DM shared common histological 
features with AD, such as fewer IRβ positive brain cells, and whether this patient group 
harboured significantly fewer IRβ positive cells in the hippocampus but not in the prefrontal 
cortex. We were unable to confirm our expectation that patients with AD plus T2DM had 
significantly fewer IRβ positive cells than the single-disease groups, but these patients had 
significantly fewer IRβ positive cells in the hippocampus. Thus, it seems that IRβ loss in the 
brain is a restricted phenomenon, and cannot decrease past a certain level. Interestingly, only 
the hippocampus (not the prefrontal cortex) was affected in patients with T2DM plus AD. 
Conditions caused by insulin abnormalities, such as T2DM, are associated with an increased 
risk of age-related cognitive decline (Luchsinger et al 2001; Peila et al 2002), possibly due to 
the lower numbers of IRβ positive cells in the hippocampus of T2DM patients observed in 
this study. We also calculated the ratio of IRß positive cells against number of all detected 
neurons. This analysis indicates that more IRβ positive cells are detected than neuron 
(supplementary table S4) in all brain regions of each group. This of course, might be due to IR 
expression in glia cells in addition to the expression in the neuronal cells. It is known that glia 
cells can express insulin receptors as well (Verdier and Penke 2004). In our study we focused 
on the changes in neuronal levels of IRβ and did not measure glial alterations. Still since it is 
documented in the literature that in AD there is an increase in glial cells (Ryu et al 2009; 
Vehmas et al 2003; Venneti et al 2009), it is rather less likely that our findings might occur 
due to changes in glial cells. However we cannot exclude the possibility whether there can be 
a “selective” neuronal cell lost of only IRβ positive neurons in AD. Since this is a very 
interesting question, we will investigate this topic further on. 
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Additionally, all patient groups possessed significantly more PPARγ(p) positive cells than the 
control group in all investigated brain regions. We were interested in PPARγ(p) because six 
months of treatment with rosiglitazone, a typical T2DM treatment and a PPARγ agonist, 
preserved cognitive function for patients with AD and amnestic mild cognitive impairment 
compared with a placebo-treated group (Watson et al 2005). A number of studies have 
examined potential mechanisms by which PPARγ agonists may ameliorate AD pathogenesis 
and progression (Landreth 2007; Neumann et al 2008); PPARγ agonists improve insulin 
sensitivity by decreasing the level of circulating insulin, increasing insulin-mediated glucose 
uptake, and enhancing insulin action in the brain, resulting in cognitive improvement (Sato et 
al 2009). The phosphorylated isoform of PPARγ is the inactive variant of this protein (Fig. 5) 
(Adams et al 1997), and therefore it was not surprising to observe higher numbers of 
PPARγ(p) positive cells in the brains of all patient groups compared to the control group. 
However, we were unable to detect between-patient-group differences, suggesting that 
PPARγ(p) is equally affected in AD and T2DM and may be why the PPARγ agonist had 
positive effects in AD patients as well as in T2DM patients. In our particular study, we 
focused on the phosphorylated form of PPARγ , which seems to play the important role in the 
pathophysiology of T2DM and maybe also in AD, but further investigations about the ration 
between phophorylated and non phosphorylated PPARγ will be necessary and will be done in 
our laboratory. 
In conclusion, T2DM and AD may not be directly linked, but may share common histological 
features including lower numbers of IRβ positive cells in the hippocampus and higher 
numbers of PPARγ(p) positive cells in the prefrontal cortex and the hippocampus. These 
observations may at least partially explain the increased frequency of AD in elderly diabetic 
patients. 
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Figure Legends 
Figure 1. Immunohistochemical staining of neuronal specific enolase (NSE) in the prefrontal 
cortex of a control case. Five fluorescent images of each brain region were recorded for each 
case. The dashed area was included in the automated cell counting. A) Cell nucleus stained in 
blue; B) cell nucleus in gray values; C) NSE staining in red; D) NSE staining in gray values. 
The arrows point to the same structure in the fluorescent and gray images. Scale bar size is 
200µm. 
 
Figure 2. Neuronal specific enolase (NSE) positive cells in post-mortem human brain samples. 
Using immunohistochemical staining against NSE in brain tissue originating from patients 
with Alzheimer’s disease (AD), with AD combined with type 2 diabetes mellitus (T2DM), 
patients with T2DM alone, and age-matched controls, alterations in NSE positive cells in the 
prefrontal cortex and in the dorsal and ventral parts of the hippocampus were evaluated. No 
statistical differences were found between the three patient groups and the control group in 
any of the investigated brain regions. 
 
Figure 3. Insulin receptor (IR) β-positive cells in post-mortem human brain samples. Using 
immunohistochemical staining against IRβ in brain tissue originating from patients with 
Alzheimer’s disease (AD), with AD combined with type 2 diabetes mellitus (T2DM), patients 
with T2DM alone, and age-matched controls, alterations in NSE positive cells in the 
prefrontal cortex and in the dorsal and ventral parts of the hippocampus were evaluated. 
Statistical analysis of IRβ positive cells was performed using ANOVA, post-hoc Scheffé; - - - 
= p< 0.05; T= nominal significance; n=10 cases/group. B. Immunohistochemical staining of 
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IRβ in hippocampus of a control case. Cell nucleus is stained in blue; IRβ is stained in red. 
The arrows point to the right structure. Scale bar size is 200µm. 
 
Figure 4. A. Phosphorylated peroxisome proliferator-activated receptor-γ (PPARγ(p))-positive 
cells in post-mortem human brain samples. Using immunohistochemical staining against 
PPARγ(p) in brain tissue originating from patients with Alzheimer’s disease (AD), with AD 
combined with type 2 diabetes mellitus (T2DM), patients with T2DM alone, and age-matched 
controls, alterations in PPARγ(p) positive cells in the prefrontal cortex and in the dorsal and 
ventral parts of the hippocampus were evaluated. Statistical analysis of PPARγ(p) positive 
cells was performed using ANOVA; post-hoc Scheffé - - - = p< 0.0001; n=10 cases/group. B. 
Immunohistochemical staining of PPARγ(p) in hippocampus of a control case. Cell nucleus is 
stained in blue; PPARγ(p) is stained in red. The arrows point to the right structure. Scale bar 
size is 200µm. 
 
Figure 5. Schematic representation of components of the system encompassing the insulin 
receptor (IR) and peroxisome proliferator-activated receptor (PPAR). Interactions between 
PPAR, MAPK/PI3K, and the IR pathways occur at various levels and are indicated as arrows 
(activation) or dots (inhibition). P = phosphorylated.      = activation;       = inhibition;  
          = transport from nucleus into cytoplasma 
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Supplementary table S1:  demographic data of postmortem brains; AD= Alzheimer disease; 
T2DM= type 2 diabetes mellitus; m=male; f=female 
 
 
 
 
Supplementary table S2: Gender differences in insulin receptor (IR) ß positive cells and 
peroxisome proliferator-activated receptor-γ (PPARγ) phosphorylated (p) in post-mortem 
human brain. 
 
 
AD= Alzheimer Disease; T2DM= Diabetes type II; m=male; f= female; MW(%)= mean value of 
enumerating cells in percent. Statistical Analysis was done via ANOVA and followed post-hoc 
Scheffé test; Bold= p <0.05. 
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Supplementary table S4:  ratio between Insulin receptor (IR) β and amount of neurons in 
postmortem brains; AD= Alzheimer disease; T2DM= type 2 diabetes mellitus. 
 
 
Region Group Ratio 
(IRβ positive 
cells/amount of 
neurons) 
Control 1.47
AD 1.14
AD+T2DM 1.58
prefrontaler Cortex T2DM 1.86
Control 1.85
AD 1.38
AD+T2DM 1.29
dorsal Hippocampus T2DM 1.05
Control 2.01
AD 1.24
AD+T2DM 1.35
ventral Hippocampus T2DM 1.88
